Chemotherapy against babesiosis

Area of Science:

• Veterinary Parasitology
• Zoonotic Diseases
• Protozoology

Background:

• Babesiosis is a significant tick-borne disease caused by protozoan parasites of the genus Babesia.
• Affects livestock, pets, and humans, causing economic losses and potential fatalities.
• Intraerythrocytic parasite development leads to severe symptoms like fever, fatigue, and hemolytic anemia.

Purpose of the Study:

• To review the current understanding of Babesiosis, its causative agents, and transmission.
• To discuss existing treatments and highlight the need for novel therapeutic strategies.
• To emphasize the importance of genomic research for developing new treatments.

Main Methods:

• Literature review of Babesiosis research, focusing on parasite biology, disease manifestations, and treatment options.
• Analysis of current therapeutic approaches, including imidocarb dipropionate, diminazene aceturate, clindamycin/quinine, and atovaquone/azithromycin.
• Examination of the role of supportive care and the potential of new drug development.

Main Results:

• Babesiosis presents a spectrum of severity, from asymptomatic to fatal, with significant economic impact in animals.
• Human babesiosis, particularly from Babesia microti and Babesia divergens, is an emerging zoonotic concern with differing clinical presentations.
• Established treatments include imidocarb dipropionate and diminazene aceturate for animals, and clindamycin/quinine or atovaquone/azithromycin for humans, alongside supportive care.

Conclusions:

• Existing babesiacides are effective but highlight the urgent need for more specific, fast-acting treatments.
• Advancements in understanding the Babesia spp. genome are crucial for facilitating the development of novel therapies.
• Increased research interest in this malaria-like parasite is essential for combating babesiosis globally.